mAbxience | Commercial Supply


We work to ensure supply of affordable medicines to health care systems worldwide, adapting to the needs of each regulatory and commercial challenged environment.

mAbxience currently has 2 biosimilars in different markets worldwide, bevacizumab and rituximab; and is presently working on a very attractive pipeline.